Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer

Docetaxel (DTX) chemotherapy remains a standard-of-care for metastatic castration-resistant prostate cancer (CRPC). DTX modestly increases survival, yet results in frequent occurrence of side-effects and resistant disease. An alternate chemotherapy with greater efficacy and minimal side-effects is n...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Babcook, Melissa A., Shukla, Sanjeev, Fu, Pingfu, Vazquez, Edwin J., Puchowicz, Michelle A., Molter, Joseph P., Oak, Christine Z., MacLennan, Gregory T., Flask, Chris A., Lindner, Daniel J., Parker, Yvonne, Daneshgari, Firouz, Gupta, Sanjay
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185215/
https://ncbi.nlm.nih.gov/pubmed/25122066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0451
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge